ANI Pharmaceuticals Inc (NASDAQ:ANIP) Director Daniel Raynor sold 27,964 shares of ANI Pharmaceuticals stock in a transaction dated Wednesday, March 14th. The stock was sold at an average price of $62.24, for a total value of $1,740,479.36. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Shares of ANI Pharmaceuticals Inc (ANIP) traded down $0.42 during trading hours on Wednesday, hitting $62.04. The stock had a trading volume of 109,024 shares, compared to its average volume of 145,615. The firm has a market cap of $727.22, a P/E ratio of 58.53 and a beta of 2.75. The company has a debt-to-equity ratio of 1.13, a current ratio of 3.36 and a quick ratio of 2.39. ANI Pharmaceuticals Inc has a 12 month low of $42.23 and a 12 month high of $74.70.
ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings data on Tuesday, February 27th. The specialty pharmaceutical company reported $1.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.02 by $0.06. The company had revenue of $47.30 million for the quarter, compared to the consensus estimate of $52.55 million. ANI Pharmaceuticals had a positive return on equity of 23.41% and a negative net margin of 0.61%. The firm’s revenue was up 23.8% compared to the same quarter last year. During the same period in the previous year, the business earned $0.84 EPS. research analysts predict that ANI Pharmaceuticals Inc will post 5.17 EPS for the current fiscal year.
ANIP has been the topic of several recent research reports. BidaskClub downgraded ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, December 21st. Canaccord Genuity set a $75.00 target price on ANI Pharmaceuticals and gave the stock a “buy” rating in a report on Saturday, December 9th. ValuEngine raised ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, November 25th. Zacks Investment Research downgraded ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, January 2nd. Finally, TheStreet raised ANI Pharmaceuticals from a “c+” rating to a “b” rating in a research note on Thursday, November 16th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $72.25.
ANI Pharmaceuticals Company Profile
ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.